Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience.
Journal
The patient
ISSN: 1178-1661
Titre abrégé: Patient
Pays: New Zealand
ID NLM: 101309314
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
19
8
2020
medline:
11
11
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Understanding the patient experience is important for identifying the unmet need in chronic lymphocytic leukemia. The current study aimed to develop a comprehensive chronic lymphocytic leukemia conceptual model. The conceptual model was based on literature searches, review of chronic lymphocytic leukemia patient blogs/forums, and interviews with five expert clinicians, with 20 patients who received at most one treatment (first line) for their chronic lymphocytic leukemia, and with 20 patients with relapsed or refractory chronic lymphocytic leukemia. De-identified interviews were transcribed, coded, and evaluated using qualitative data analysis software. Thirty-five prevalent chronic lymphocytic leukemia-related symptom and impact concepts were identified from literature searches, patient blogs/forums, and clinician interviews. Patient interviews confirmed the identified concepts and revealed five additional concepts. Fatigue-related sub-components were identified from how patients described their fatigue, covering symptoms (tiredness/need for sleep, lack of energy, weakness, cognitive fatigue), and impacts (decreased ability to maintain their social, familial, or professional role, decreased physical functioning, frustration). Three versions of the conceptual model were created: an overall model with all concepts; a model highlighting the most prominent concepts in first line; and a model highlighting the most prominent concepts in relapsed or refractory disease. Prominent concepts in both first line and relapsed or refractory disease were fatigue-related symptoms and impacts, muscle/joint aches, night sweats, bruising, fever, recurrent infections/illness, insomnia, decreased cognitive/emotional functioning, anxiety/worry, stress, depression, financial difficulty, and fear of death. Dyspnea and cough were prominent in first line only, and enlarged lymph nodes, headaches, pain/discomfort, weight loss, nausea/vomiting, and infusion reactions were prominent in relapsed or refractory disease only. The results show that fatigue is a dominant issue affecting patients with chronic lymphocytic leukemia. The three versions of the conceptual model can help researchers to understand patients' unmet needs and guide the patient-reported outcome strategy for clinical trials.
Sections du résumé
BACKGROUND AND OBJECTIVE
Understanding the patient experience is important for identifying the unmet need in chronic lymphocytic leukemia. The current study aimed to develop a comprehensive chronic lymphocytic leukemia conceptual model.
METHODS
The conceptual model was based on literature searches, review of chronic lymphocytic leukemia patient blogs/forums, and interviews with five expert clinicians, with 20 patients who received at most one treatment (first line) for their chronic lymphocytic leukemia, and with 20 patients with relapsed or refractory chronic lymphocytic leukemia. De-identified interviews were transcribed, coded, and evaluated using qualitative data analysis software.
RESULTS
Thirty-five prevalent chronic lymphocytic leukemia-related symptom and impact concepts were identified from literature searches, patient blogs/forums, and clinician interviews. Patient interviews confirmed the identified concepts and revealed five additional concepts. Fatigue-related sub-components were identified from how patients described their fatigue, covering symptoms (tiredness/need for sleep, lack of energy, weakness, cognitive fatigue), and impacts (decreased ability to maintain their social, familial, or professional role, decreased physical functioning, frustration). Three versions of the conceptual model were created: an overall model with all concepts; a model highlighting the most prominent concepts in first line; and a model highlighting the most prominent concepts in relapsed or refractory disease. Prominent concepts in both first line and relapsed or refractory disease were fatigue-related symptoms and impacts, muscle/joint aches, night sweats, bruising, fever, recurrent infections/illness, insomnia, decreased cognitive/emotional functioning, anxiety/worry, stress, depression, financial difficulty, and fear of death. Dyspnea and cough were prominent in first line only, and enlarged lymph nodes, headaches, pain/discomfort, weight loss, nausea/vomiting, and infusion reactions were prominent in relapsed or refractory disease only.
CONCLUSIONS
The results show that fatigue is a dominant issue affecting patients with chronic lymphocytic leukemia. The three versions of the conceptual model can help researchers to understand patients' unmet needs and guide the patient-reported outcome strategy for clinical trials.
Identifiants
pubmed: 32808103
doi: 10.1007/s40271-020-00440-9
pii: 10.1007/s40271-020-00440-9
pmc: PMC7794108
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-87Références
Leuk Lymphoma. 2017 Jul;58(7):1598-1606
pubmed: 27830957
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46
pubmed: 30855005
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Gen Hosp Psychiatry. 2007 May-Jun;29(3):251-6
pubmed: 17484943
Leuk Res. 2009 Feb;33(2):263-70
pubmed: 18656259
Leuk Lymphoma. 2018 Sep;59(9):2075-2084
pubmed: 29295653
Leuk Lymphoma. 2005 Dec;46(12):1709-14
pubmed: 16263572
Value Health. 2016 Jan;19(1):42-52
pubmed: 26797235
Br J Haematol. 2008 Dec;143(5):690-7
pubmed: 19016733
Contemp Oncol (Pozn). 2015;19(5):361-7
pubmed: 26793019
Br J Haematol. 2007 Oct;139(2):255-64
pubmed: 17897301
Sex Disabil. 2016;34(4):367-388
pubmed: 27881887
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Leuk Lymphoma. 2009 Feb;50(2):171-8
pubmed: 19197731
BMJ Open. 2018 Feb 3;8(2):e017282
pubmed: 29431123
Acta Oncol. 2016 Sep - Oct;55(9-10):1115-1120
pubmed: 27494089
Am J Hematol. 2017 Sep;92(9):946-965
pubmed: 28782884
J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178
pubmed: 30959516
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Cancer Control. 2015 Oct;22(4 Suppl):7-16
pubmed: 26618341
Eur J Cancer Care (Engl). 2012 Jan;21(1):67-77
pubmed: 21883563
Qual Life Res. 2018 Feb;27(2):333-345
pubmed: 29127596
Lancet Haematol. 2017 Feb;4(2):e67-e74
pubmed: 28089238
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
Pharmacoeconomics. 2016 May;34(5):479-98
pubmed: 26739956
Lancet Haematol. 2018 Nov;5(11):e563-e598
pubmed: 29907552
Leuk Lymphoma. 2017 Feb;58(2):399-407
pubmed: 27357445
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Cancer. 2015 Sep 15;121(18):3335-42
pubmed: 26079197
Support Care Cancer. 2013 Oct;21(10):2853-60
pubmed: 23748484
N Engl J Med. 2013 Aug 1;369(5):397-400
pubmed: 23822654
Psychol Health. 2016 Jul;31(7):891-902
pubmed: 26982998
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7
pubmed: 30249389
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752